Berenberg downgrades GSK to 'hold' ahead of product rollouts.

Analysts at Berenberg downgraded drugmaker GSK from 'buy' to 'hold' on Tuesday as it awaited upcoming product launches.

GSK
03 June 2025 10:51:51

Source: Sharecast

Berenberg said GSK has delivered 12% absolute share price performance year-to-date, the highest in the sector, but despite this, continues to trade roughly 30% below the value of its marketed drugs alone.

The German bank stated that a better-than-anticipated start to any of GSK's upcoming product rollouts could "reinvigorate investor interest" and begin to address 2028+ HIV patent expiry fears.

However, Berenberg expects investors to adopt "a show-me attitude" and noted that while GSK's valuation "remains unchallenging", it prefers Sanofi for pharma value investors.

"GSK trades on 8.7x 2026 adjusted earnings versus non-obesity European peers on 11.5x. On EV/NPV, GSK trades c15% below European non-obesity peers (0.70x versus 0.82x) and c30% below the value of marketed assets alone," said Berenberg, which reiterated its £16.00 target price.

Reporting by Iain Gilbert at Sharecast.com

FTSE 100 ( UKX )

ISIN: N/A

Exchange: London Stock Exchange

Sell:

0.00

Buy:

0.00

Change: 3.72 ( 0.04 %)

Date:

06/06/2025 - 10:00

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.